淡江大學機構典藏:Item 987654321/109463
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 64178/96951 (66%)
造访人次 : 9910630      在线人数 : 20020
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/109463


    题名: No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment
    作者: Hung, Tsung-Hsing;Tsai, Chen-Chi;Tseng, Chih-Wei;Tseng, Kuo-Chih;Hsieh, Yu-Hsi;Tsai, Chih-Chun
    关键词: esophageal variceal bleeding;renal function impairment;somatostatin;terlipressin
    日期: 2016-11
    上传时间: 2017-02-21 02:10:31 (UTC+8)
    摘要: Objective
    To study the differences in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding (EVB) and renal functional impairment (RFI).

    Methods
    The National Health Insurance Database, part of the Taiwan National Health Insurance Program, was used to enroll cirrhotic patients who had received endoscopic variceal ligation plus somatostatin or terlipressin for EVB and who were hospitalized between 1 January 2007 and 31 December 2010. The differences in mortality between the two vasoactive agents were compared and the risk factors for 30-day mortality because of EVB were identified.

    Results
    A total of 2324 cirrhotic patients with EVB were enrolled. The 30-day mortality data showed no significant differences between the somatostatin and the terlipressin groups (P=0.232). The risk of 30-day mortality was significantly higher in male patients [hazard ratio (HR): 1.50, P=0.002] and patients with hepatic encephalopathy (HR: 1.82, P<0.001), ascites (HR: 1.32, P=0.008), bacterial infections (HR: 2.10, P<0.001), hepatocellular carcinoma (HR: 2.09, P<0.001), and RFI (HR: 3.89, P<0.001). A subgroup analysis of cirrhotic patients with RFI was carried out. The overall 30-day mortality was higher in patients treated with somatostatin than in those treated with terlipressin (52.6 vs. 42.3%), but the difference failed to reach significance (adjust HR: 1.49, 95% confidence interval: 0.94–2.37, P=0.091).

    Conclusion
    RFI was the most important risk factor for 30-day mortality in EVB patients. Terlipressin and somatostatin had similar effects on 30-day mortality in cirrhotic patients with EVB and RFI.
    關聯: European Journal of Gastroenterology & Hepatology 28(11), p.1275–1279
    DOI: 10.1097/MEG.0000000000000703
    显示于类别:[應用數學與數據科學學系] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML320检视/开启
    No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment.pdf288KbAdobe PDF0检视/开启

    在機構典藏中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回馈